Skip to main content
OpenTrials
Completed

NCT Number: NCT07591961

Identifying the Microbial Metabolome: The Missing Link Between Diet and Human Health

There is a lot of evidence to suggest that the bacteria in our gut play a major role in maintaining our health, but very little is known about the way in which this is achieved. In this study we will identify how the bacteria in out gut change the food we eat into products that may be responsible for this effect. We will also identify which bacteria are responsible for these changes. The foods we will look at are those suggested by the American Institute of Cancer Research to help prevent cancer; leafy green vegetables (cabbage, spinach), soft fruits (strawberry) cereal (oats) and plant-based protein (soya and pea). We will feed a diet rich in these foods to volunteers, monitoring the changes to the bacteria in our gut and the products produced. We will identify which products have potential to prevent cancer and also to work out how they are being produced. This work will provide new and important information that will allow us to understand more about the link between diet and health.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

An accumulation of evidence indicates that the gut microbiota plays a vital role in inflammation and in the development of many diseases including diabetes, cardiovascular disease and cancer (Vijay-Kumar et al; 2010, Masklowski et al; 2009, Clarke et al 2010). Despite tremendous advances in the molecular approaches describing the composition of the human gut microbiota (Qin et al; 2012), to date relatively little is known about the functionality and role of even the most dominant commensal organisms within the human host. It is widely accepted that the products of microbial metabolism influence human health and disease, particularly regarding inflammation and immune responses. Despite this, many of the products of microbial metabolism of dietary compounds remain uncharacterised and consequently, their mechanisms of action unknown. As an enormous investment is being made to continue to characterise the microbiome and its interaction with the human immune system, there is now a critical requirement that the functional role of the microbiota is established. It is important that in addition to describing the microbial populations, the species are also defined by their function and metabolic outputs. This topic is exceptionally timely as there is increasing pressure to provide healthy food to a growing and increasingly unhealthy and aging population. Elucidating the products of microbial metabolism provides an essential and missing link between well-defined dietary intakes and the physiological effect of dietary constituents. Without this information, the nutritional value of food cannot be fully established, food claims effectively evaluated, nor the contribution of the gut microbiota to an overall aim of developing sustainable agricultural products beneficial for human health ascertained.

Diet, is a major factor shaping the composition of the colonic microbial community as well as a principal determinant of the gut metabolome. This is likely to explain why it is also a contributing factor in disease development and progression. Two related dietary factors appear to play a significant role in maintaining the equilibrium between health and disease. Firstly, the balance between different types of carbohydrate and protein is fundamental. Dietary fibre intake is strongly correlated with prevention of carcinogenesis and evidence that high protein-low carbohydrate diets are detrimental to health is increasing. Secondly, there is a large amount of literature suggesting that plant secondary metabolites have anti-cancer properties. In particular, almost all plant foods considered to have cancer-preventative properties are rich in non-nutrient compounds derived from the phenylpropanoid pathway. Much of the evidence for this however is obtained from in vitro data and there is very little evidence from both pre-clinical and human interventions to support their bioavailability and role in carcinogenesis. Data regarding the metabolism and bioavailability of phytochemicals is lacking, particularly with reference to transformation by the gut microbiota and absorption from the colon via the hepatic circulation. Additionally, the relationship between the main macronutrients (carbohydrate and protein) and non-nutrient phytochemicals is poorly understood. It is likely that it is a combination of these dietary factors that modulates both the gut bacteria and the overall metabolite profile, both in the gut and in the systemic circulation. This unique proposal will address the combined effects of the macro- and non-nutrient components of the diet, along with the gut microbial composition on the production of microbial metabolites.

Study Objectives

Specific objectives of the project are to:

  • Fully characterise dietary substrates in terms of their macro-, micro- and non-nutrient phytochemicals, providing the basis for detailed in vitro work and rigorous human intervention studies.
  • Identify the microbial metabolites which exhibit inflammatory activity at relevant in vivo concentrations. This will provide essential information, not currently available and will inform wider studies looking at the action of microbial metabolites on particular receptors and biomarkers of health.
  • Determine the functionality of the bacterial species responsible in terms of metabolite production. In this context, this will also identify the extent of redundancy of certain species.
  • Establish the role of major macronutrients in driving microbial metabolism, both in the production of phytochemical metabolites and the provision of carbohydrate and protein by-products.

Hypothesis Phytochemicals bound to plant polymers reach the colon largely intact and are metabolised and released by the gut microbiota where they can exert a direct anti-inflammatory action on the gut mucosa. Additionally mucosal uptake of these metabolites will suppress low-level chronic systemic inflammation. Furthermore, the source and type of polymer may improve or exacerbate the effect.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Volunteers will be:

  • healthy male or females
  • aged between 18 and 55 years
  • able to give informed consent.

Exclusion criteria

Volunteers will be excluded if they:

  • are taking any medicines prescribed by their GP
  • are taking drugs to lower high cholesterol levels or high blood pressure
  • regularly take analgesics, antipyretic or anti-inflammatories
  • regularly take nutritional supplements
  • have taken antibiotics in the last three months
  • have given a large blood donation in last three months

Treatment and study plan

Food

Dietary Supplement

The intervention products will be consumed as bread rolls, each containing 33.3 g of the intervention product. Three rolls will be consumed per day during the five day intervention period, in addition to the prescribed low-phytochemical diet.

Primary outcomes

  1. Gut Microbial Metabolites

    Time frame: At Day 3

    Wide range of beneficial and detrimental microbial metabolites in faeces, blood and urine

  2. Gut Microbial Metabolites

    Time frame: At Day 5

    Wide range of beneficial and detrimental microbial metabolites in faeces, blood and urine

Secondary outcomes

  1. Gut Microbial Species

    Time frame: At Day 3

    Bacteria

    Wide range of gut bacteria present in faecal samples

  2. Gut Microbial Species

    Time frame: At Day 5

    Bacteria

Sponsors and collaborators

Lead sponsor

University of Aberdeen

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

Identifying Microbial Metabolites and the Bacteria Responsible for Their Formation

Important dates

Study start
2016
Primary completion
2019
Study completion
2019
First posted
May 18, 2026
Registry last updated
May 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.